NASDAQ: MXCTMaxcyte Inc Stock
$4.43+0.24 (+5.73%)
Updated Dec 11, 2024
MXCT Price
$4.43
Fair Value Price
N/A
Market Cap
$467.29M
52 Week Low
$3.17
52 Week High
$5.55
P/E
-13.03x
P/B
2.19x
P/S
8.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$45.60M
Earnings
-$35.74M
Gross Margin
86%
Operating Margin
-78.37%
Profit Margin
-78.4%
Debt to Equity
0.17
Operating Cash Flow
-$19M
Beta
1.5
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MXCT Overview
MaxCyte Incorporated develops technologyies that use blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites. Its products (MaxCyte STX, VLX, and GT) are used in cell therapy, including gene editing, immuno-oncology and in drug biomanunfacturing applications. MaxCyte was incorporated in 1998 and is headquartered in Gaithersburg, MD.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MXCT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Value
D
Growth
C
Momentum
B
Sentiment
C
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important MXCT news, forecast changes, insider trades & much more!
MXCT News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MXCT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MXCT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MXCT is good value based on its book value relative to its share price (2.19x), compared to the US Medical Devices industry average (4.05x)
P/B vs Industry Valuation
MXCT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MXCT due diligence checks available for Premium users.
Valuation
MXCT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.03x
Industry
36.96x
Market
29.76x
MXCT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.19x
Industry
4.05x
MXCT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MXCT's financial health
Profit margin
Revenue
$8.2M
Net Income
-$11.6M
Profit Margin
-141.6%
MXCT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MXCT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$248.6M
Liabilities
$35.3M
Debt to equity
0.17
MXCT's short-term assets ($172.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MXCT's short-term assets ($172.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MXCT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.4M
Investing
$3.6M
Financing
$228.0k
MXCT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MXCT vs Medical Device Stocks
Maxcyte Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.